Abstract. Previous studies have indicated that type II cyclic guanosine monophosphate (cGMP)-dependent protein kinase (PKG II) could inhibit the proliferation and migration of gastric cancer cells. However, the effects of PKG II on the biological functions of other types of cancer cells remain to be elucidated. Therefore, the aim of the present study was to investigate the effects of PKG II on cancer cells derived from various types of human tissues, including A549 lung, HepG2 hepatic, OS-RC-2 renal, SW480 colon cancer cells and U251 glioma cells. Cancer cells were infected with adenoviral constructs coding PKG II (Ad-PKG II) to up-regulate PKG II expression, and treated with 8-(4-chlorophenylthio) (8-pCPT)-cGMP to activate the kinase. A Cell Counting kit 8 assay was used to detect cell proliferation. Cell migration was measured using a Transwell assay, whereas a terminal deoxynucleotidyl transferase 2'-deoxyuridine, 5'-triphosphate nick-end labeling assay was used to detect cell apoptosis. A pull-down assay was used to investigate the activation of Ras-related C3 botulinum toxin substrate (Rac) 1 and western blotting was used to detect the expression of proteins of interest. The present results demonstrated that EGF (100 ng/ml, 24 h) promoted the proliferation and migration of cancer cells, and it suppressed their apoptosis. In addition, treatment with EGF enhanced the activation of Rac1, and up-regulated the protein expression of proliferating cell nuclear antigen, matrix metalloproteinase (MMP)2, MMP7 and B-cell lymphoma (Bcl)-2, whereas it down-regulated the expression of Bcl-2-associated X protein.
Introduction
The 'hallmarks of cancer', as suggested by Hanahan and Weinberg (1), comprise 10 common biological traits shared by cancer cells, that are acquired during the tumor development process, including sustained proliferation, resistance to cell death, invasive and metastatic capabilities. Therefore, the development of therapeutic strategies targeting the aforementioned biological traits, and the associated gene expression and signaling pathways, is critical for the effective treatment of patients with cancer.
Cyclic guanosine monophosphate (cGMP)-dependent protein kinase type II (PKG II) is a structurally and functionally distinct membrane-bound enzyme. As a Ser/Thr kinase, PKG II has been reported to serve a role in intestinal secretion, bone growth, and learning and memory (2) (3) (4) . In addition, previous studies have suggested that PKG II may be associated with tumor pathogenesis: PKG II has been reported to suppress cancer cell proliferation, including human colon and prostatic stromal cancer cells and glioma cells (5) (6) (7) , and promote the apoptosis of breast cancer cells (8, 9) . Preliminary research demonstrated that the expression and activity of PKG II appeared to be down-regulated in human gastric cancer cells compared with normal gastric mucosal cells (10) . In addition, PKG II was demonstrated to inhibit the proliferation and migration, and enhance the apoptosis of gastric cancer cells (11) (12) (13) . The molecular mechanisms underlying the effects of PKG II on cancer cells were also investigated: PKG II was observed to inhibit epidermal growth factor (EGF)-induced EGF receptor (EGFR) Tyr phosphorylation and activation, and to subsequently inhibit mitogen-activated protein kinase kinase (MAPK)/extracellular signal-regulated kinase (ERK), phospholipase (PL) Cγ1 and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (Akt)-mediated signal transduction pathways, initiated by EGF/EGFR activation in gastric cancer cells (11) (12) (13) . However, the putative anti-cancer effects of PKG II on other types of cancer cells, apart from gastric cancer cells, remain to be investigated. Therefore, the present study aimed to investigate the actions of PKG II in vitro on several types of cancer cells derived from various tissues, including human A549 lung, HepG2 hepatic, OS-RC-2 renal, SW480 colon cancer and U251 glioma cells. The effects of PKG II on the proliferation, migration and apoptosis of the aforementioned cells were investigated and the molecular mechanisms that were involved were explored. Human lung cancer cell line A549,  hepatic cancer cell line HepG2, renal cancer cell line OS-RC-2,  colon cancer cell line SW480 and glioma cell line U251 were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin (HyClone; GE Healthcare Life Sciences, Logan, UT, USA), in a humidified incubator at 37˚C and 5% CO 2 . When cells grew to ~80 confluence they were sub-cultured. Adenoviral vectors encoding the cDNA of β-galactosidase (Ad-LacZ) and PKG II (Ad-PKG II) were kind gifts from Dr Gerry Boss and Dr Renate Pilz (Department of Medicine, University of California, San Diego, CA, USA). 8-(4-chlorophenylthio)-cGMP (8-pCPT-cGMP), a cell-permeable cGMP analog, was purchased from EMD Millipore (Billerica, MA, USA 10 pfu/ml Ad-LacZ or Ad-PKG II for 24 h at 37˚C, serum-starved for 12 h, and then treated with 8-pCPT-cGMP (250 µΜ) for 1 h, followed by treatment with EGF (100 ng/ml) for 12 or 24 h. Subsequently, ~10 µl CCK8 solution was added to each well and incubated for 30 min at 37˚C. The optical density of each well at 450 nm was measured using a microplate reader. Data were presented as a percentage of the OD value of the control group. Experiments were performed in triplicate.
Materials and methods

Cell lines and reagents.
Cell migration assay. The migratory capabilities of cancer cells were assessed using a Transwell assay. Following trypsinization, 5x10 4 cells were seeded into the upper chambers of the Transwell inserts, which contained DMEM without FBS.
Cell migration to the lower membrane was induced by medium containing 10% FBS in the lower chamber for 12-24 h. The non-migrated cells in the upper chamber were carefully removed. Cells migrated to the lower membrane were fixed with 4% paraformaldehyde at 4˚C for 30 min, stained in 0.07% Giemsa solution for 10 min at room temperature, and rinsed in water. Stained cells were observed under a light microscope and counted in 5 randomly selected fields/insert. Experiments were performed in triplicate.
Detection of apoptosis using TUNEL assay. Cells were seeded in 24-well plates (5x10 4 cells/well), cultured in FBS-free DMEM and treated with Ad-PKG II, 8-pCPT-cGMP and EGF, as mentioned above. The cells were then fixed with 4% paraformaldehyde for 30 min at room temperature, washed three times with PBS, and then permeabilized with 1% Triton X-100 for 4 min at 4˚C. Subsequently, 500 µl terminal deoxynucleotidyl transferase (TdT)-labeled nucleotide mix was added to each well and the plate was kept at 37˚C for 60 min in the dark. The wells were rinsed twice with PBS and then counterstained with 10 mg/ml 4,6-diamidino-2-phenylindole (OriGene Technologies, Inc., Beijing, China) for 5 min at 37˚C washed with PBS and covered with coverslip. Apoptotic cells were characterized by a dark-brown staining of the nucleus and nuclear membrane. Quantification was performed by counting the number of positive cells in 4 randomly chosen fields within each x200 frame using an Olympus microscope (BX43, Olympus, Japan). Image-Pro Plus version 6.0 software (Media Cybernetics, Boston, MA, USA) was used to quantify the TUNEL-positive cells. Experiments were performed in triplicate.
Pull-down assay of active small G protein Rac1. The activity of Rac1 was assessed using a pull-down assay. Cells were infected with Ad-PKG II, treated with 8-pCPT-cGMP (250 µΜ) for 1 h and with EGF (100 ng/ml) for 5 min, and then lysed in lysis buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 1% NP40, 10% glycerol, 25 mM NaF, 10 mM MgCl 2 , 0.25% sodium deoxycholate, 1 mM EDTA, 1 mM Na 3 VO 4 , 10 mg/ml aprotinin and 10 mg/ml leupeptin) (14) . The protein extracts were incubated with glutathione-Sepharose beads and glutathione S-transferase-Rac-RBD (GST-RBD) at 4˚C for 1 h. The activated Rac1 bound to the beads and total Rac1 in cell extracts was detected using western blot analysis with antibodies against Rac1. Experiments were performed in triplicate.
Western blot analysis. Cells were treated with Ad-PKGII, 8-pCPT-cGMP or EGF according to the different groups, and lysed in lysis buffer (5% β-mercaptoethanol, 1% bromophenol blue, 0.2% SDS, 25% glycerinum, 12.5% 0.5M Tris-HCl and 35.5% H 2 O) for 5 min at 100˚C. Proteins were quantified using a bicinchoninic acid protein assay kit (cat. no. P0009; Beyotime Institute of Biochemistry, Beijing, China). Equal quantities of protein (40 µg) were separated by 10% SDS-PAGE, prior to transferring proteins onto polyvinylidene difluoride membranes (0.4 µm; EMD Millipore, Billerica, MA, USA). The membranes were blocked in 5% BSA in TBST (0.1% Tween-20) for 1 h at 4˚C and incubated with primary antibodies as stated in section of cell lines and reagents for 12 h at 4˚C, followed by incubation with the corresponding secondary antibodies as stated in section of cell lines and reagents for 1 h at room temperature, with 3 washes by TBST (0.1% Tween-20) following each incubation. Protein bands were visualized using ECL reagents (EMD Millipore, Billerica, MA, USA) and analyzed by Tanon MP version 4.1.2 software (Tanon Science and Technology Co., Ltd., Shanghai, China).
Statistical analysis.
All experiments were performed in triplicate. Data are expressed as the mean ± standard deviation. One-way analysis of the variance and Fisher's least significant difference post hoc tests were performed to evaluate the differences among groups. Statistical analysis was performed using SPSS version 13.0 software (SPSS, Inc., Chicago, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
PKG II inhibits EGF induced-proliferation in cancer cells.
The proliferative activity of various types of cancer cells was assessed using a CCK8 assay. The present results indicated that following EGF (100 ng/ml) stimulation for 24 h, the numbers of living cells were increased by 1.89-, 1.22-, 1.53-, 1.68-and 1.51-fold in A549, HepG2, OS-RC-2, SW480 and U251 cells, respectively (P<0.05; Fig. 1 ). However, when cells were infected with Ad-PKG II to enhance PKG II expression, and subsequently stimulated with 8-pCPT-cGMP (250 µΜ) for 1 h to activate the kinase, EGF treatment was demonstrated to have no effect on cellular proliferation (Fig. 1) . These findings suggested that activated PKG II may inhibit the EGF-induced increase of proliferation in various types of cancer cell lines.
PKG II inhibits EGF-induced PCNA expression. The expression of PCNA, which is considered a direct and reliable indication of cell proliferation, was detected in cancer cells using western blot analysis (15) . The present results demonstrated that across all 5 cancer cell lines, the protein expression of PCNA in EGF-treated cells was significantly increased compared with in untreated cells (P<0.05; Fig. 2A-F) . Infection with Ad-PKG II and stimulation with 8-pCPT-cGMP (250 µΜ) caused 60.3, 68.1, 55.4, 65.6 and 54.1% reductions in PCNA expression in A549, HepG2, OS-RC-2, SW480 and U251 cells, respectively, compared with the Ad-LacZ + EGF group (P<0.05; Fig. 2A-F) . These observations suggested that PKG II may suppress the processes of DNA replication in various types of tumor cell lines.
PKG II inhibits EGF induced-migration in cancer cells.
Cancer cells were infected with Ad-LacZ or Ad-PKG II, treated with 8-pCPT-cGMP and EGF, and cell migration was assessed using a Transwell migration assay. The results demonstrated that the numbers of migrated cells were increased following EGF treatment (100 ng/ml) for 12 h, indicating that EGF enhanced the migratory activity of cancer cells (P<0.05; Fig. 3A and B). Following transfection with Ad-PKG II and stimulation with 8-pCPT-cGMP, the numbers of migrated cells were reduced by 61.5, 83.2, 55.9, 54.2 and 50.1% in A549, HepG2, OS-RC-2, SW480 and U251 cells, respectively, compared with the Ad-LacZ + cGMP + EGF group (P<0.05; Fig. 3A and B) . These results suggested that PKG II may inhibit the enhancing effects of EGF stimulation on cancer cell migration in vitro.
PKG II inhibits the activation of Rac1. Small G protein Rac1 is the main member of the Rho family of guanosine-5'-triphosphatases (GTPases), and serves a critical role in cell migration (16) . Rac1 exists in 2 forms in cells: The GTP-bound active form and the guanosine diphosphate-bound inactive form. Once Rac1 is in its GTP-bound form, it can bind and activate Raf-1 and initiate the activating cascade of Ser/Thr protein kinases in the signaling pathway (17,18). To investigate whether the inhibitory effect of PKG II on cancer cell migration may be associated with the activation of Rac1, a pull-down assay was used to isolate and detect activated Rac1. The present results demonstrated that EGF stimulation resulted in the marked increase of active Rac1; conversely, PKG II overexpression was identified to efficiently inhibit the activation of Rac1 in various types of cancer cells (Fig. 4) .
PKG II inhibits the EGF-induced expression of MMP2 and MMP7.
MMPs serve an important role in tissue remodeling, which has been associated with pathological processes, including cancer cell metastasis (19) . MMP2 and MMP7 have been suggested to be critical for metastasis (20) . In order to investigate the effects of PKG II on cancer cell metastasis, the protein expression of MMP2 and MMP7 was assessed. The present results demonstrated that EGF treatment (100 ng/ml) resulted in the significant upregulation of MMP2 and MMP7 protein expression levels (P<0.05; Fig. 5A-F) . Conversely, the 
PKG II reverses the anti-apoptotic effects of EGF in cancer cells.
Apoptosis is a type of programmed cell death, during which cells undergo morphological changes, including cell shrinkage, nuclear fragmentation and chromosomal DNA fragmentation (21) . TUNEL is a method for detecting DNA fragmentation by labeling the terminal ends of nucleic acids; in the present study, apoptotic cells were stained dark brown. EGF treatment was demonstrated to reduce the apoptosis of A549 cells by 85.4%, of HepG2 cells by 80.6%, of OS-RC-2 cells by 49.0%, of SW480 cells by 58.6%, and of U251 cells by 46.9% (P<0.05; Fig. 6 ). However, among cells transfected with Ad-PKG II and incubated with 8-pCPT-cGMP, the apoptotic cells were increased by >2-fold compared with EGF-stimulated cells (P<0.05; Fig. 6 ). These results suggested that activated PKG II may counteract the anti-apoptotic effects of EGF in various types of cancer cells.
PKG II reverses EGF-induced expression of apoptosis-regulating proteins.
The Bcl-2 family contains pro-apoptotic proteins such as Bax, Bcl-2-associated death promoter and Bcl-2 homologous antagonist/killer, and anti-apoptotic proteins such as Bcl-2 and Bcl-2-like protein 2 (22) . Among the various Bcl-2 family members, the Bcl-2/Bax ratio is taken as an effective index indicating the apoptotic activities (23) . In the present study, the effects of PKG II on the protein expression of Bcl-2 and Bax were investigated using western blot analysis. The present results demonstrated that across all types of cancer cells, the protein expression of Bcl-2 was up-regulated following EGF treatment (100 ng/ml) for 12 h; however, no marked alteration in Bax expression was detected in EGF-treated cells (Fig. 7A-E) . Notably, when cells were infected with Ad-PKG II and stimulated with 8-pCPT-cGMP, EGF treatment did not appear to enhance the expression of Bcl-2; however, the expression of Bax appeared to be increased compared with the Ad-LacZ group (Fig. 7A-E) . These results indicated that PKG II suppressed the expression of the anti-apoptotic Bcl-2 and stimulated the expression of pro-apoptotic Bax, thus causing a significant decrease in the Bcl-2/Bax ratio (P<0.05; Fig. 7F ).
Discussion
cGMP-dependent signaling pathways have been reported to participate in the biological functions of tumor cells (4) , and the roles of PKG I in tumorigenesis have been investigated, thus identifying PKG I as a tumor suppressor (24) (25) (26) . Previous studies have suggested that PKG II may also exert inhibitory effects on the development of some tumor types (5, 27) ; however, the detailed effects of PKG II on the biological activity of cancer cells have yet to be elucidated. In the present study, the putative antitumor properties of PKG II were investigated in various types of cancer cells.
In a previous study, the expression and activity of PKG II were identified to be downregulated in cancer cell lines compared with in normal cells (10) . Therefore, in the present study, cancer cells were infected with a PKG II-encoding adenoviral vector, in order to increase the protein expression of PKG II; subsequently, its roles in tumorigenesis were investigated. In the present study, various human cancer cell lines, including A549 lung, HepG2 hepatic, OS-RC-2 renal, SW480 colon cancer and U251 glioma cell lines, were infected with Ad-PKG II to induce PKG II overexpression. Western blot analysis demonstrated that PKG II expression was significantly up-regulated in Ad-PKG II-infected cells compared with in control cells, and it was maintained at a high level for >96 h (data not shown).
A CCK8 assay was used to investigate the effects of PKG II on the proliferative activity of various types of cancer cells. The present results demonstrated that cellular proliferation was significantly enhanced following EGF treatment; however, the stimulating effects of EGF were eliminated following PKG II overexpression and activation with 8-pCPT-cGMP. The CCK8 assay does not distinguish between the inhibition of proliferation and the induction of apoptosis as the mechanism underlying the decrease in live cell numbers. Therefore, the anti-proliferative effects of PKG II were further examined.
PCNA is a DNA clamp which acts as a processivity factor for DNA polymerase δ in eukaryotic cells, and is required for DNA replication (28) . Antibodies against PCNA have been used for tumor grading, and they also have a diagnostic and prognostic value (29) . Therefore, the expression of PCNA, as a marker of cancer cell proliferation, was detected, and the results demonstrated that PKG II inhibited the EGF-induced up-regulation of PCNA expression across all 5 cancer cell lines. These results indicated that PKG II overexpression and activation inhibited the proliferation of cancer cells in vitro.
The pro-apoptotic effects of PKG II were also examined using a TUNEL assay. In accordance with our previous results in gastric and breast cancer cells (8, 30) , EGF stimulation was identified to suppress the apoptosis of A549, HepG2, OS-RC-2, SW480 and U251 cancer cells, whereas PKG II could reverse the anti-apoptotic effects of EGF. In order to further investigate the implication of PKG II in cancer cell apoptosis, its effects on the expression of apoptosis-associated proteins were also examined. The present results demonstrated that PKG II down-regulated the expression of the anti-apoptotic protein Bcl-2, whereas it enhanced the expression of the pro-apoptotic protein Bax. These results suggested that PKG II overexpression may inhibit the proliferation and also induce the apoptosis of various types of cancer cells in vitro. These results are in accordance with the results of a previous study in gastric cancer cells (30) . In combination with the previous results, it may be hypothesized that the effects of PKG II on the proliferation and apoptosis of cancer cells are associated with the inhibition of EGFR tyrosine phosphorylation/activation and EGF/EGFR-mediated signal transduction, including MAPK/ERK (12), MAPK/Janus kinase (8) , and PI3K/Akt-mediated signaling (30) .
Metastasis is among the key causes of cancer-associated mortality of patients. Cell migration is closely associated with cancer metastasis, and the acquisition of migratory capabilities is critical for cancer cells to reach distant organs (31) . EGF has been reported to stimulate cancer cell migration (32) . Our previous study indicated that PKG II could inhibit the migration of gastric cancer cells, via blocking EGF/EGFR triggered-PLCγ1-and MAPK/ERK-mediated pathways (11) . To investigate the putative inhibitory effects of PKG II on the migratory capabilities of various types of cancer cells, a Transwell migration assay was used. The present results indicated that activated PKG II inhibited the EGF-stimulated migration of A549, HepG2, OS-RC-2, SW480 and U251 cells in vitro. In addition, the effects of PKG II on invasion-associated proteins were also examined. MMPs are major proteolytic enzymes and can degrade almost all protein components of the extracellular matrix (ECM), thus destroying the tissue barriers to tumor cell invasion, and serve a key role in cancer invasion and metastasis (33) . The present results demonstrated that following PKG II overexpression, the expression of MMP2 and MMP7 was downregulated, thus suggesting that PKG II may inhibit the degradation of ECM protein components and suppress the metastatic potential of cancer cells.
In conclusion, the present study demonstrated that PKG II overexpression inhibited the EGF-induced potentiation of the migratory and proliferative capabilities of cancer cells. In addition, it counteracted the anti-apoptotic effects of EGF stimulation in several types of cancer cells, including lung, colon, liver, kidney cancer and glioma. A preliminary investigation of the molecular mechanisms that were involved indicated that PKG II overexpression resulted in the decreased expression of the proliferation index PCNA, the metastasis-associated proteins MMP2 and MMP7, and the anti-apoptotic protein Bcl-2; conversely, it up-regulated the expression of the pro-apoptotic protein Bax in cancer cells. These results suggested that PKG II may exert inhibitory effects on the growth and metastasis in various types of cancer cells derived from several tissues, and suggested a role for endogenous PKG II as a potential tumor suppressor. Our findings will provide theoretical support for the potential treatment of cancer patients with big molecular inhibitors, especially protein molecules. Furthermore, since PKG II is an endogenous protein kinase, its potential application in treatment of cancers can avoid some side-effect such as immunologic rejection and poisonous effects. This will suggest new strategy for cancer treatment. 
